Trial Profile
Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection: Observational Retrospective Study at 48 Weeks - KIRAL Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 May 2017
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms KIRAL
- 22 May 2017 New trial record